ライフサイエンスコーパス: growth restriction

1 l conditions, including stillbirth and fetal growth restriction.

2 sulted in reduced placental weight and fetal growth restriction.

3 r for preterm birth, preeclampsia, and fetal growth restriction.

4 l inflammation and was associated with fetal growth restriction.

5 as identified in humans with early postnatal growth restriction.

6 o acid transporter activity and causes fetal growth restriction.

7 ral malformations and linked to intrauterine growth restriction.

8 ations, uteroplacental dysfunction, or fetal growth restriction.

9 d preterm newborns without evidence of fetal growth restriction.

10 response to hypoxia, a major cause of fetal growth restriction.

11 thological process of interest, intrauterine growth restriction.

12 impaired spiral artery remodeling with fetal growth restriction.

13 en, especially those at higher risk of fetal growth restriction.

14 utero-placental perfusion, hypertension and growth restriction.

15 l age and those with pathologic intrauterine growth restriction.

16 onal hypoxia such as pre-eclampsia and fetal growth restriction.

17 t of its dehydrogenase activity, even during growth restriction.

18 cental growth factor levels and intrauterine growth restriction.

19 proliferation, including fetal and postnatal growth restriction.

20 ous abortion, preeclampsia, and intrauterine growth restriction.

21 s, hearing and vision loss, and intrauterine growth restriction.

22 from maternal blood and contributes to fetal growth restriction.

23 obactin critical for overcoming SCN-mediated growth restriction.

24 anistic link between pre-eclampsia and fetal growth restriction.

25 nerational family with four members who have growth restriction.

26 was preceded by preeclampsia or intrauterine growth restriction.

27 ce or absence of ultrasonic markers of fetal growth restriction.

28 ger delivery in mothers of babies with fetal growth restriction.

29 status who were at low risk of intrauterine growth restriction.

30 status who were at low risk of intrauterine growth restriction.

31 omes of human pregnancy complicated by fetal growth restriction.

32 icated with intervillositis, can cause fetal growth restriction.

33 play a role in the pathophysiology of fetal growth restriction.

34 eral are of pathological relevance for fetal growth restriction.

35 worldwide and is often complicated by fetal growth restriction.

36 ling responses, and contributes to bacterial growth restriction.

37 ria, and edema) and, in some patients, fetal growth restriction.

38 y disorders including preeclampsia and fetal growth restriction.

39 association between race/ethnicity and fetal growth restriction.

40 ulation is associated with fetal hypoxia and growth restriction.

41 o analyze the role of T6P/SnRK1 in relief of growth restriction.

42 ike systemic acquired resistance or pathogen growth restriction.

43 even when undamaged, shows JA-dependent leaf growth restriction.

44 stational day 14.5 that induced intrauterine growth restriction.

45 nfirming that LOX3 and LOX4 function in leaf growth restriction.

46 gical AMPK activation for treatment of fetal growth restriction.

47 cy disorders such as pre-eclampsia and fetal growth restriction.

48 haly, spontaneous abortion, and intrauterine growth restriction.

49 ignaling contributed to late-gestation fetal growth restriction.

50 term safety regarding potential craniofacial growth restriction.

51 tions, such as preeclampsia and intrauterine growth restriction.

52 previous pre-eclampsia or intrauterine fetal growth restriction.

53 ed disorders, such as preeclampsia and fetal growth restriction.

54 a) protects against hypoxia-associated fetal growth restriction.

55 l characteristics of preeclampsia with fetal growth restriction.

56 are associated with poor outcomes like fetal growth restriction.

57 ation; 1.16, 1.01-1.34; I(2)=64%), and fetal growth restriction (1.26, 1.20-1.33; I(2)=1%).

58 An atmosphere of 13% oxygen induced fetal growth restriction (1182 +/- 9 mg, n = 90 vs. 1044 +/- 1

59 6 [22%] vs 2/71 [3%]; p=0.002), intrauterine growth restriction (34/37 [92%] vs 34/70 [48%]; p<0.0001

60 ntrast, paternally transmitted hIC1 leads to growth restriction, abnormal hIC1 methylation, and loss

61 ith pregnancies characterized by fetal loss, growth restriction, abnormal placental development, and

62 principal 13-LOXs responsible for vegetative growth restriction after repetitive wounding.

63 tion, intra-amniotic inflammation, and fetal growth restriction, all of which are clinical signs asso

64 els indicate that (a) therapies which induce growth restriction among metastases but do not prevent i

65 o mechanisms and interventions against fetal growth restriction and adult-onset programmed hypertensi

66 HA pregnancy led to chronic fetal hypoxia, growth restriction and altered cardiovascular function.

67 IO prevented approximately half of the fetal growth restriction and attenuated placental insufficienc

68 High-altitude hypoxia causes intrauterine growth restriction and cardiovascular programming.

69 incident CHF, atrial arrhythmias, and fetal growth restriction and complex CHD was associated with v

70 ect of diabetes on oogenesis, leads to fetal growth restriction and congenital deformities.

71 weaning induces a linear correlation between growth restriction and DNA methylation at ribosomal DNA

72 Stillbirth is associated with both growth restriction and excessive fetal growth.

73 Hypoxic pregnancy induced fetal growth restriction and fetal oxidative stress.

74 D at GD14 and GD18 in association with fetal growth restriction and higher blood pressure.

75 y be due to conditions associated with fetal growth restriction and iatrogenic preterm birth.

76 , whilst heterozygous loss resulted in fetal growth restriction and impaired placental formation and

77 ant dams during early pregnancy led to fetal growth restriction and infection of the fetal brain in W

78 o abortion, premature delivery, intrauterine growth restriction and low birth weight.

79 ating fetal outcomes, including intrauterine growth restriction and microcephaly.

80 Here we show that both fetal growth restriction and over-growth are associated with g

81 ental development, resulting in intrauterine growth restriction and perinatal lethality.

82 Here, we developed a mouse model of fetal-growth restriction and placental insufficiency that is i

83 cental villous tissue occurred in both fetal growth restriction and pre-eclampsia, whereas CD79alpha(

84 placental perfusion, leading to intrauterine growth restriction and preeclampsia, is the failure of i

85 ith pregnancy disorders such as intrauterine growth restriction and preeclampsia, which are character

86 ion of pregnancy complications such as fetal growth restriction and preeclampsia.

87 ent with antioxidants protects against fetal growth restriction and programmed hypertension in adulth

88 on and oxidative stress; and in the fetus as growth restriction and progressive hypoxemia.

89 nd metabolic pathways required for bacillary growth restriction and reactivation.

90 r Dnm3b) mimics nutritional models of kidney growth restriction and results in a substantial reductio

91 uish placental dysfunction from intrauterine growth restriction and reveal a role for the placenta in

92 dition of the placenta associated with fetal growth restriction and stillbirth.

93 Placental insufficiency can cause fetal growth restriction and stillbirth.

94 is a significant mechanism underlying fetal growth restriction and the programming of adverse health

95 have suggested an association between fetal growth restriction and the risk of spontaneous preterm b

96 egnancy outcomes in severe early-onset fetal growth restriction and therefore it should not be prescr

97 of placentas from newborns with intrauterine growth restriction and underlying congenital HCMV infect

98 a role in the investigation of intrauterine growth restriction and unexplained stillbirth.

99 tions are associated with proportional fetal growth restriction and with an increased risk of preterm

100 tas from pregnancies with severe early-onset growth-restriction and preeclampsia displaying abnormal

101 ses who had preeclampsia and/or intrauterine growth restriction) and 2 cases that could not be suffic

102 us and is associated with fetal death, fetal growth restriction, and a spectrum of central nervous sy

103 low birth weight (LBW), preterm birth, fetal growth restriction, and birth defects among births to wo

104 ts can cause poor placentation, intrauterine growth restriction, and early parturition leading to pre

105 ity, stillbirth, preterm birth, intrauterine growth restriction, and fetal congenital anomalies, eith

106 ge, fetal death, preterm birth, intrauterine growth restriction, and fetal microcephaly, collectively

107 nificantly increased placental damage, fetal growth restriction, and fetal resorption.

108 diseases such as preeclampsia, intrauterine growth restriction, and gestational diabetes.

109 mutant embryos exhibit gene dosage-dependent growth restriction, and homozygous mutants exhibit upper

110 includes babies born preterm and with fetal growth restriction, and not all these infants have a bir

111 tetric outcomes such as pre-eclampsia, fetal growth restriction, and preterm birth.

112 transmission, pup viral loads, intrauterine growth restriction, and pup mortality comparable to that

113 ns of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.

114 y complications, such as preeclampsia, fetal growth restriction, and stillbirth.

115 (aOR, 1.42; 95% CI, 1.08-1.86), intrauterine growth restriction (aOR, 1.17; 95% CI, 1.01-1.37), low b

116 t that TNL-triggered cell death and pathogen growth restriction are determined by distinctive feature

117 Increased morbidity and fetal growth restriction are reported in uninfected children b

118 severe forms of preeclampsia or intrauterine growth restriction, are thought to arise from failures i

119 -term birth, pre-eclampsia, and intrauterine growth restriction-are common interrelated disorders cau

120 Pre-eclampsia and fetal growth restriction arise from disorders of placental dev

121 We defined fetal growth restriction as a combination of estimated fetal w

122 s understanding and interpretations of fetal growth restriction as represented by small for gestation

123 th normal pregnancies, particularly in fetal growth restriction associated with pre-eclampsia.

124 Hypoxia-related fetal growth restriction becomes apparent between 25 and 29 wk

125 s population, all children were experiencing growth restriction but differences in magnitude were inf

126 Both models lead to intrauterine growth restriction but dissociate between a situation wh

127 were each characterized by worsening linear growth restriction but varied in the timing and severity

128 evels in pregnancy are associated with fetal growth restriction, but the underlying mechanisms are po

129 itamin D deficiency has been linked to fetal growth restriction, but the underlying mechanisms are un

130 acco exposure has been associated with fetal growth restriction, but uncertainty remains about critic

131 ase that counteracts intracellular bacterial growth restriction by phytate.

132 The process of wound-response growth restriction can be recapitulated in unwounded pla

133 Severe early-onset fetal growth restriction can lead to a range of adverse outcom

134 that metastases must undergo to escape from growth restriction, cannot be extracted from relapse dat

135 Extrauterine growth restriction, catch-up growth, altered adiposity,

136 Prevention of Preeclampsia and Intrauterine Growth Restriction cohort, multiple serial assessments w

137 f rat MOv18 IgE demonstrated superior tumour growth restriction compared with rat MOv18 IgG (tumour o

138 the mouse Mtrr gene results in intrauterine growth restriction, developmental delay, and congenital

139 Fetal outcomes included growth restriction, distress, and death.

140 associated with a greater incidence of fetal growth restriction due, in part, to lesser uterine arter

141 es of pregnancy pathologies, including fetal growth restriction, due at least in part to reductions i

142 umption led to placental inefficiency, fetal growth restriction, elevated fetal serum glucose and tri

143 lacental growth retardation and intrauterine growth restriction, evidence of placental and fetal brai

144 ues characterize 5 individuals who exhibited growth restriction, facial deformities, and a history of

145 It was found that besides of growth restriction factor by pinning behavior on grain b

146 he alloy compositions are converted to their growth restriction factors (Q) and that increasing Q had

147 irment, behavioral alterations, intrauterine growth restriction, feeding problems, and various congen

148 otrophoblasts, leading to intrauterine fetal growth restriction, fetal liver hypocellularity, and dem

149 lability causes human diseases such as fetal growth restriction, fetal malformations and cancer.

150 e availability causes diseases such as fetal growth restriction, fetal malformations and cancer.

151 Fetal growth restriction (FGR) affects 5% to 10% of newborns a

152 Fetal growth restriction (FGR) affects around 5% of pregnancie

153 Fetal growth restriction (FGR) and pre-eclampsia are severe, a

154 Fetal growth restriction (FGR) and preeclampsia (PE) are often

155 motherhood and short birth intervals, fetal growth restriction (FGR) and preterm birth, child nutrit

156 maternal age (AMA) are susceptible to fetal growth restriction (FGR) and stillbirth.

157 Preeclampsia (PE) and fetal growth restriction (FGR) are serious complications of pr

158 o identify metabolites associated with fetal growth restriction (FGR) by examining early and late pre

159 lacental vessel networks in normal and fetal growth restriction (FGR) complicated pregnancies.

160 Fetal growth restriction (FGR) is a major risk factor for stil

161 Fetal growth restriction (FGR) is a significant risk factor fo

162 Fetal growth restriction (FGR) is associated with global adver

163 Fetal growth restriction (FGR) is the major single cause of st

164 Fetal growth restriction (FGR) results from placental insuffic

165 eclamptic pregnancies complicated with fetal growth restriction (FGR) with and without villitis of un

166 most common and preventable causes of fetal growth restriction (FGR), a condition in which a fetus i

167 Fetal growth restriction (FGR), a major risk factor for stillb

168 They are associated with fetal growth restriction (FGR), but previous studies have not

169 adverse pregnancy outcomes, including fetal growth restriction (FGR), due in part to reductions in n

170 l pregnancies and those complicated by fetal growth restriction (FGR).

171 tery remodeling (ISAR) with or without fetal growth restriction (FGR).

172 may be indicative of local ischemia or fetal growth restriction (FGR).

173 ive aetiologies in the pathogenesis of fetal growth restriction (FGR); however, the regulating sites

174 syndromic coronal craniosynostosis to severe growth restriction, fulfilling diagnostic criteria for M

175 ana) leaves, but the 13-LOXs responsible for growth restriction have not yet been identified.

176 F1 or IGF1R cause intrauterine and postnatal growth restriction; however, data on mutations in IGF2,

177 eeks of gestation who had very preterm fetal growth restriction (ie, low abdominal circumference [<10

178 t the fetal-maternal interface, intrauterine growth restriction, impaired placental development, and

179 rvival of neural progenitors and reduces the growth restriction imposed by Aspm deletion.

180 The severe growth restriction in affected family members suggests t

181 Placental sO2 was lower in fetal growth restriction in an angiotensin-converting enzyme 2

182 OM ARABIDOPSIS THALIANA6 expression and that growth restriction in BOP1/2 gain-of-function plants req

183 is supported by Hmox1 and ameliorates fetal-growth restriction in Hmox1 deficiency.

184 (OR, 31.8; 95% CI, 4.3-236.3) CHD, for fetal growth restriction in noncomplex (OR, 1.6; 95% CI, 1.3-2

185 y; Sildenafil does not protect against fetal growth restriction in the chick embryo, supporting the i

186 ation is a key feature of nutritional kidney growth restriction in vitro and in vivo, and that DNA me

187 Markers of fetal growth restriction included biometric ratios, utero-plac

188 -borne virus recently linked to intrauterine growth restriction including abnormal fetal brain develo

189 found that ZIKV infection leads to postnatal growth restriction including microcephaly.

190 KV(BR) infects fetuses, causing intrauterine growth restriction, including signs of microcephaly, in

191 Overcoming cellular growth restriction, including the evasion of cellular se

192 glucose homeostasis and is altered by fetal growth restriction induced by maternal undernutrition.

193 associated with amniotic band formation and growth restriction induced in rats by amniocentesis, as

194 Fetal growth restriction is a major determinant of adverse per

195 Intrauterine growth restriction is associated with a nephron deficit

196 Intrauterine growth restriction is associated with shorter blood cell

197 a sexually dimorphic response; intrauterine growth restriction is associated with substantially grea

198 dNK inhibition, the risk of pre-eclampsia or growth restriction is increased.

199 ritical exposure windows and timing of fetal growth restriction is limited.

200 eclinical studies suggests that intrauterine growth restriction is protective against later inflammat

201 Intrauterine growth restriction (IUGR) affects up to 10% of pregnanci

202 Placental insufficiency causes intrauterine growth restriction (IUGR) and disturbances in glucose ho

203 l and postnatal factors such as intrauterine growth restriction (IUGR) and high-fat (HF) diet contrib

204 al nutrient restriction induces intrauterine growth restriction (IUGR) and leads to heightened cardio

205 Intrauterine growth restriction (IUGR) and low birth weigth (LBW) are

206 residence increases the risk of intrauterine growth restriction (IUGR) and preeclampsia 3-fold, augme

207 ce/ethnicity is associated with intrauterine growth restriction (IUGR) and small-for-gestational age

208 (HA) increases the incidence of intrauterine growth restriction (IUGR) approximately threefold.

209 for gestational age (SGA) from intrauterine growth restriction (IUGR) as independent predictors of R

210 Intrauterine growth restriction (IUGR) confers heritable alterations

211 Intrauterine growth restriction (IUGR) decreases serum IGF-1 levels.

212 Intrauterine growth restriction (IUGR) enhances risk for adult onset

213 Fetuses with intrauterine growth restriction (IUGR) have lower muscle mass that pe

214 Fetuses with intrauterine growth restriction (IUGR) have reduced muscle mass that

215 revious studies in fetuses with intrauterine growth restriction (IUGR) have shown that adrenergic dys

216 s such as preeclampsia (PE) and intrauterine growth restriction (IUGR) in 20% of patients.

217 KEY POINTS: Intrauterine growth restriction (IUGR) increases offspring risk of ch

218 Intrauterine growth restriction (IUGR) increases the risk for metabol

219 Intrauterine growth restriction (IUGR) is a common complication of pr

220 Intrauterine growth restriction (IUGR) is a pathology of pregnancy th

221 Intrauterine growth restriction (IUGR) is associated with perinatal m

222 Intrauterine growth restriction (IUGR) is associated with specific ch

223 Intrauterine fetal growth restriction (IUGR) is often associated with compr

224 Intrauterine growth restriction (IUGR) leads to development of type 2

225 Intrauterine growth restriction (IUGR) leads to offspring obesity.

226 Placental insufficiency and intrauterine growth restriction (IUGR) of the fetus affects approxima

227 We hypothesized that intrauterine growth restriction (IUGR) offspring hearts would show im

228 e also evaluated the effects of intrauterine growth restriction (IUGR) on carotenoid status in term n

229 was to determine the impact of intrauterine growth restriction (IUGR) on pancreatic vascularity and

230 l muscle mass in the fetus with intrauterine growth restriction (IUGR) persists into adulthood and ma

231 Intrauterine growth restriction (IUGR) reduces skeletal muscle mass i

232 KEY POINTS: Rodent models of intrauterine growth restriction (IUGR) successfully identify mechanis

233 Rodent models of intrauterine growth restriction (IUGR) successfully identify mechanis

234 TS: Adults who were affected by intrauterine growth restriction (IUGR) suffer from reductions in musc

235 ndrome that is characterized by intrauterine growth restriction (IUGR) with gonadal, adrenal, and bon

236 to decreased beta cell growth, intrauterine growth restriction (IUGR), and impaired placental develo

237 al nutrient restriction induces intrauterine growth restriction (IUGR), increasing later life chronic

238 rnal nutrient reduction induces intrauterine growth restriction (IUGR), increasing risks of chronic d

239 olic syndrome (MetS), following intrauterine growth restriction (IUGR), is epigenetically heritable.

240 ion process are associated with Intrauterine Growth Restriction (IUGR), Preeclampsia (PE) and High El

241 hown to prevent preeclampsia or intrauterine growth restriction (IUGR).

242 in mid-gestation lethality and intrauterine growth restriction (IUGR).

243 fection is also associated with intrauterine growth restriction (IUGR).

244 ed in placentas of infants with intrauterine growth restriction (IUGR).

245 he main etiological factors for intrauterine growth restriction (IUGR).

246 les had offspring with third-trimester fetal growth restriction, leading to a smaller head circumfere

247 characterized by short stature, intrauterine growth restriction, lipoatrophy and a facial gestalt inv

248 rus may also be associated with intrauterine growth restriction, low birth weight, and fetal death, b

249 r the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth.

250 ssive disorder characterized by severe fetal growth restriction, microcephaly, a distinct facial appe

251 Screening procedures for fetal growth restriction need to identify small babies and the

252 provide a potential mechanism for the fetal growth restriction observed in women who use cannabis du

253 Postnatal growth restriction occurred in pups in UPI/RA, but not i

254 However, growth restriction of bacteria lacking PlcA, PlcB, and A

255 tophagic processes responsible for bacterial growth restriction of Listeria monocytogenesL.

256 treated patients triggered acidification and growth restriction of M. tuberculosis in macrophages.

257 breast cancer cell survival in vitro and in growth restriction of orthotopic breast cancer xenograft

258 phyB-independent growth restriction of the jazD mutant was tightly correl

259 We then tested 39 patients with severe growth restriction of unknown etiology, and found hypome

260 luated the effect of malaria on intrauterine growth restriction on the basis of the fetal growth rate

261 after implantation, along with intrauterine growth restriction or embryonic death.

262 confounding factors, including intrauterine growth restriction or factors related to the cause of in

263 had used LMWH); and 11 cases of intrauterine growth restriction or placental insufficiency (5 women h

264 utcomes (N = 29) and those with intrauterine growth restriction or preeclampsia (N = 12).

265 the effect of potential confounders such as growth restriction or prematurity remain to be elucidate

266 paired placental function, either with fetal growth restriction or preterm labour, or both.

267 in, headache with visual disturbances, fetal growth restriction, or abnormal maternal blood tests tha

268 tion without congenital malformations, fetal growth restriction, or severe postnatal morbidity.

269 ransport are decreased in human intrauterine growth restriction our data are consistent with the poss

270 AR partially prevented hypoxia-induced fetal growth restriction (P < 0.01), due in part to increased

271 eight (<2500 g), pre-term birth (<37 weeks), growth restriction, pre-eclampsia, miscarriage and/or st

272 ancy-related disorders such as intra uterine growth restriction, preeclampsia and preterm birth.

273 cause severe fetal complications, including growth restriction, preterm birth, and stillbirth.

274 ic fluid and/or newborn saliva, intrauterine growth restriction, preterm deliveries, and controls.

275 gnancy complications, including intrauterine growth restriction, preterm delivery, and stillbirth.

276 hese meta-analyses suggest that intrauterine growth restriction protects against allergic diseases in

277 mice died perinatally associated with fetal growth restriction, reduced hepatic glycogen stores, and

278 e to determine whether hypoxia-induced fetal growth restriction reduces placental PPAR-gamma protein

279 ment of pregnancies at risk for intrauterine growth restriction relies on accurate identification and

280 Wound-response plant growth restriction requires the synthesis of potent medi

281 I, 0.62 to 0.95]), 1% to 5% for intrauterine growth restriction (RR, 0.80 [CI, 0.65 to 0.99]), and 2%

282 lood flow and relative protection from fetal growth restriction seen in altitude-adapted Andean popul

283 t Nations population and causes intrauterine growth restriction, severe microcephaly, craniofacial an

284 ection in pregnant women causes intrauterine growth restriction, spontaneous abortion, and microcepha

285 ations, including preeclampsia, intrauterine growth restriction, spontaneous abortion, preterm birth,

286 Prevention of Preeclampsia and Intrauterine Growth Restriction) study were followed up to 10.8 years

287 rnutrition in the aggregate--including fetal growth restriction, stunting, wasting, and deficiencies

288 33S(;)P168S] variant in ROP and intrauterine growth restriction suggests that it also may be a marker

289 cy complication associated with intrauterine growth restriction that may influence respiratory outcom

290 oactive ingredient in cannabis, causes fetal growth restriction, though the mechanisms are not well u

291 placental malaria per se, might cause fetal growth restriction, through impaired transplacental gluc

292 an expanded adipose tissue results from cell growth restriction to prevent cell necrosis.

293 days' gestation and severe early-onset fetal growth restriction to receive either sildenafil 25 mg th

294 rnal exposure to Cd is associated with fetal growth restriction, trace element deficiencies, and cong

295 cental villous tissue are increased in fetal growth restriction vs. placentas from women with normal

296 Maternal undernutrition contributes to fetal growth restriction, which increases the risk of neonatal

297 tal pathologies associated with intrauterine growth restriction, which is a significant cause of infa

298 lasma FA concentrations in a baboon model of growth restriction with data that suggest adaptation of

299 resulted in pups born with symmetrical fetal growth restriction, with catch up growth by post-natal d

300 le, maternal smoking (Z) is a cause of fetal growth restriction (X), which subsequently affects prete